News

Nabriva in antibiotics deal with Forest
Enlarge image

BusinessAustria

Nabriva in antibiotics deal with Forest

04.06.2012 - Austrian biotech Nabriva Therapeutics AG has partnered with Forest Laboratories Inc. to develop its antibiotic BC-3781.

Vienna - As part of the deal, Forest will have the exclusive right to acquire Nabriva for the next 12 months. Nabriva will receive US$25m. Forest will also fund and help develop BC-3781 during the period.  BC-3781 belongs to a novel class of antibiotics, the pleuromutilins. It is designed to treat severe and drug resistant infections including MRSA, penicillin-resistant Streptococcus pneumonia, Legionella pneumophila, which causes Legionnaires' disease, and Chlamydophila pneumoniae, a major cause of pneumonia. 

BC-3781 has potential in both intravenous and oral formulations and the cooperating companies plan to advance it into Phase III testing early next year. Forest said the oral formulation provides an opportunity to treat patients after they leave the hospital and would complement its Teflaro ceftaroline, a cephalosporin antibiotic available only as an intravenous drug. 

Nabriva is based in Vienna, and in 2011 it reported positive mid-stage trial results from a Phase IIb  study that evaluated BC-3781 as a treatment for acute bacterial and skin structure infections. 

http://www.european-biotechnology-news.com/news/news/2012-02/nabriva-in-antibiotics-deal-with-forest.html

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

M&ASwitzerland

09.06.2015 Monsanto plans to acquire Syngenta AG, but seems reluctant to dig deep into its pockets. The Swiss crop chemical maker has now rejected the second offer from the US company.

InnovationPolandEU

05.06.2015 Polish drug maker Polpharma has received a €45m loan from the European Investment Bank to further its biosimilar research. The operation is part of InnovFin, a new programme set up to support innovative research.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOCUTIS (UK)0.22 GBP15.79%
  • ADOCIA (F)68.80 EUR9.21%
  • WILEX (D)3.90 EUR8.94%

FLOP

  • SANTHERA (CH)89.00 CHF-5.82%
  • OXFORD BIOMEDICA (UK)9.15 GBP-5.67%
  • NEUROVIVE PHARMACEUTICAL AB (S)21.90 SEK-5.19%

TOP

  • PROTHENA PLC (IE)51.28 USD30.0%
  • DBV Technologies (F)52.65 EUR22.4%
  • BIOINVENT INTERNATIONAL AB (S)2.61 SEK17.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)21.90 SEK-54.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • CELLECTIS (F)31.83 EUR-22.2%

TOP

  • ADOCIA (F)68.80 EUR386.2%
  • WILEX (D)3.90 EUR358.8%
  • 4SC (D)4.39 EUR352.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • ACTIVE BIOTECH (S)9.00 SEK-69.6%
  • NEOVACS (F)1.19 EUR-67.5%

No liability assumed, Date: 29.06.2015